Drug-eluting versus bare-metal stent implantation with or without cilostazol in the treatment of the superficial femoral artery: The debate in SFA study

Circulation: Cardiovascular Interventions

Volumn 11, Issue 8, 2018, Pages

  Miura, Takashi ^a   Miyashita, Yusuke ^b,c   Soga, Yoshimitsu ^d   Hozawa, Koji ^e   Doijiri, Tatsuki ^f   Ikeda, Uichi ^a,b   Kuwahara, Koichiro ^b  

^a Nagano Municipal Hospital   (Japan)

^b SHINSHU UNIVERSITY HOSPITAL   (Japan)

^c NAGANO RED CROSS HOSPITAL   (Japan)

^d KOKURA MEMORIAL HOSPITAL   (Japan)

^e NEW TOKYO HOSPITAL   (Japan)

^f SEIWA HOSPITAL   (Japan)

Author keywords

Amputation; Drug eluting stents; Femoral artery incidence; Stents

Indexed keywords

ACETYLSALICYLIC ACID; CILOSTAZOL; CLOPIDOGREL; CARDIOVASCULAR AGENT; METAL;

ADVERSE OUTCOME; AGED; ARTICLE; BLEEDING; CHRONIC TOTAL OCCLUSION; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DEVICE SAFETY; DRUG DOSE REDUCTION; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; DUPLEX DOPPLER ULTRASONOGRAPHY; EDEMA; FEMALE; FOLLOW UP; HEART PALPITATION; HUMAN; IMPLANTATION; IN-STENT RESTENOSIS; LIMB AMPUTATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; PEAK SYSTOLIC VELOCITY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SUPERFICIAL FEMORAL ARTERY; TARGET LESION REVASCULARIZATION; AMPUTATION; CLINICAL TRIAL; COMPARATIVE STUDY; DEVICES; DIAGNOSTIC IMAGING; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG ELUTING STENT; ENDOVASCULAR SURGERY; FEMORAL ARTERY; LIMB SALVAGE; MIDDLE AGED; MORTALITY; PATHOPHYSIOLOGY; PROSTHESIS DESIGN; RECURRENT DISEASE; RISK FACTOR; STENT; TIME FACTOR; TREATMENT OUTCOME; VASCULAR PATENCY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; AMPUTATION; CARDIOVASCULAR AGENTS; CILOSTAZOL; DOUBLE-BLIND METHOD; DRUG-ELUTING STENTS; ENDOVASCULAR PROCEDURES; FEMALE; FEMORAL ARTERY; HUMANS; LIMB SALVAGE; MALE; METALS; MIDDLE AGED; PERIPHERAL ARTERIAL DISEASE; PROSPECTIVE STUDIES; PROSTHESIS DESIGN; RECURRENCE; RISK FACTORS; STENTS; TIME FACTORS; TREATMENT OUTCOME; ULTRASONOGRAPHY, DOPPLER, DUPLEX; VASCULAR PATENCY;

EID: 85055597127     PISSN: 19417640     EISSN: 19417632     Source Type: Journal    
DOI: 10.1161/CIRCINTERVENTIONS.118.006564     Document Type: Article

References (23)

1. Zeller T. Current state of endovascular treatment of femoro-popliteal artery disease. Vasc Med. 2007;12:223-234. doi: 10.1177/1358863X07079823
2. Balzer JO, Thalhammer A, Khan V, Zangos S, Vogl TJ, Lehnert T. Angioplasty of the pelvic and femoral arteries in PAOD: results and review of the literature. Eur J Radiol. 2010;75:48-56. doi: 10.1016/j.ejrad.2010.04.016
3. Morris-Stiff G, Ogunbiyi S, Rees J, Davies CJ, Hicks E, Lewis MH. Variations in the anatomical distribution of peripheral vascular disease according to gender. Ann R Coll Surg Engl. 2011;93:306-309. doi: 10.1308/003588411X571999
4. Krankenberg H, Schlüter M, Steinkamp HJ, Bürgelin K, Scheinert D, Schulte KL, Minar E, Peeters P, Bosiers M, Tepe G, Reimers B, Mahler F, Tübler T, Zeller T. Nitinol stent implantation versus percutaneous translumi-nal angioplasty in superficial femoral artery lesions up to 10 cm in length: the femoral artery stenting trial (FAST). Circulation. 2007;116:285-292. doi: 10.1161/CIRCULATIONAHA.107.689141
5. Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG; TASC II Working Group. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J Vasc Surg. 2007;45 (suppl S):S5-S67. doi: 10.1016/j.jvs.2006.12.037
6. Soga Y, Iida O, Hirano K, Yokoi H, Nanto S, Nobuyoshi M. Mid-term clinical outcome and predictors of vessel patency after femoropopliteal stenting with self-expandable nitinol stent. J Vasc Surg. 2010;52:608-615. doi: 10.1016/j.jvs.2010.03.050
7. Ohki T, Angle JF, Yokoi H, Jaff MR, Popma J, Piegari G, Kanaoka Y; OSPREY Investigators. One-year outcomes of the U.S. and Japanese regulatory trial of the Misago stent for treatment of superficiaal femoral artery disease (OSPREY study). J Vasc Surg. 2016;63:370-376.e1. doi: 10.1016/j.jvs.2015.08.093
8. Iida O, Yokoi H, Soga Y, Inoue N, Suzuki K, Yokoi Y, Kawasaki D, Zen K, Urasawa K, Shintani Y, Miyamoto A, Hirano K, Miyashita Y, Tsuchiya T, Shinozaki N, Nakamura M, Isshiki T, Hamasaki T, Nanto S; STOP-IC Investigators. Cilostazol reduces angiographic restenosis after endovascular therapy for femoropopliteal lesions in the Sufficient Treatment of Peripheral Intervention by Cilostazol study. Circulation. 2013;127:2307-2315. doi: 10.1161/CIRCULATIONAHA.112.000711
9. Tosaka A, Soga Y, Iida O, Ishihara T, Hirano K, Suzuki K, Yokoi H, Nanto S, Nobuyoshi M. Classification and clinical impact of restenosis after femoropopliteal stenting. J Am Coll Cardiol. 2012;59:16-23. doi: 10.1016/j.jacc.2011.09.036
10. Dake MD, Ansel GM, Jaff MR, Ohki T, Saxon RR, Smouse HB, Machan LS, Snyder SA, O'Leary EE, Ragheb AO, Zeller T; Zilver PTX Investigators. Durable clinical effectiveness with paclitaxel-eluting stents in the femoropopliteal artery: 5-year results of the Zilver PTX randomized trial. Circulation. 2016;133:1472-1483; discussion 1483. doi: 10.1161/CIRCULATIONAHA.115.016900
11. Iida O, Takahara M, Soga Y, Nakano M, Yamauchi Y, Zen K, Kawasaki D, Nanto S, Yokoi H, Uematsu M; ZEPHYR Investigators. 1-year results of the ZEPHYR registry (Zilver PTX for the Femoral Artery and Proximal Popliteal Artery): predictors of restenosis. JACC Cardiovasc Interv. 2015;8:1105-1112. doi: 10.1016/j.jcin.2015.03.022
12. Kamioka N, Soga Y, Kuramitsu S, Iida O, Hirano K, Suzuki K, Kawasaki D, Yamaoka T, Suematsu N, Shintani Y, Miyashita Y, Takahashi H, Tsuchiya T, Shinozaki N, Okazaki S, Ando K. Clinical outcomes of balloon angioplasty alone versus nitinol stent implantation in patients with small femoropopliteal artery disease: observations from the Retrospective Multicenter Analysis for Femoropopliteal Stenting (REAL-FP). Catheter Cardiovasc Interv. 2017;90:790-797. doi: 10.1002/ccd.27192
13. Laird JR, Schneider PA, Tepe G, Brodmann M, Zeller T, Metzger C, Krishnan P, Scheinert D, Micari A, Cohen DJ, Wang H, Hasenbank MS, Jaff MR; IN.PACT SFA Trial Investigators. Durability of treatment effect using a drug-coated balloon for femoropopliteal lesions: 24-month results of IN.PACT SFA. J Am Coll Cardiol. 2015;66:2329-2338. doi: 10.1016/j.jacc.2015.09.063
14. Soga Y, Takahara M, Iida O, Suzuki K, Hirano K, Kawasaki D, Shintani Y, Yamaoka T, Ando K. Relationship between primary patency and lesion length following bare nitinol stent placement for femoropopliteal disease. J Endovasc Ther. 2015;22:862-867. doi: 10.1177/1526602815610118
15. Zeller T, Peeters P, Bosiers M, Lammer J, Brechtel K, Scheinert D, Rastan A, Noory E, Beschorner U. Heparin-bonded stent-graft for the treatment of TASC II C and D femoropopliteal lesions: the Viabahn-25 cm trial. J Endovasc Ther. 2014;21:765-774. doi: 10.1583/14-4790R.1
16. Iida O, Takahara M, Soga Y, Hirano K, Yamauchi Y, Zen K, Kawasaki D, Nanto S, Yokoi H, Uematsu M; ZEPHYR Investigators. The characteristics of in-stent restenosis after drug-eluting stent implantation in femoropopliteal lesions and 1-year prognosis after repeat endovascular therapy for these lesions. JACC Cardiovasc Interv. 2016;9:828-834. doi: 10.1016/j.jcin.2016.01.007
17. Miyashita Y, Saito S, Miyamoto A, Iida O, Nanto S. Cilostazol increases skin perfusion pressure in severely ischemic limbs. Angiology. 2011;62:15-17. doi: 10.1177/0003319710371619
18. Sudo T, Tachibana K, Toga K, Tochizawa S, Inoue Y, Kimura Y, Hidaka H. Potent effects of novel anti-platelet aggregatory cilostamide analogues on recombinant cyclic nucleotide phosphodiesterase isozyme activity. Biochem Pharmacol. 2000;59:347-356.
19. Kimura Y, Tani T, Kanbe T, Watanabe K. Effect of cilostazol on platelet aggregation and experimental thrombosis. Arzneimittelforschung. 1985;35(7A):1144-1149.
20. Kawamura K, Watanabe K, Kimura Y. Effect of cilostazol, a new anti-thrombotic drug, on cerebral circulation. Arzneimittelforschung. 1985;35(7A):1149-1154.
21. Takahashi S, Oida K, Fujiwara R, Maeda H, Hayashi S, Takai H, Tamai T, Nakai T, Miyabo S. Effect of cilostazol, a cyclic AMP phosphodiesterase inhibitor, on the proliferation of rat aortic smooth muscle cells in culture. J Cardiovasc Pharmacol. 1992;20:900-906.
22. Tomoi Y, Kuramitsu S, Soga Y, Aihara H, Ando K, Nobuyoshi M. Vascular response after Zilver PTX stent implantation for superficial femoral artery lesions: serial optical coherence tomography findings at 6 and 12 months. J Endovasc Ther. 2015;22:41-47. doi: 10.1177/1526602814566577
23. Kimura T, Yokoi H, Nakagawa Y, Tamura T, Kaburagi S, Sawada Y, Sato Y, Yokoi H, Hamasaki N, Nosaka H. Three-year follow-up after implantation of metallic coronary-artery stents. N Engl J Med. 1996;334:561-566. doi: 10.1056/NEJM199602293340903